Chart, page-2071

First 2071 Last

Share
Profile

Follow
manny100

5,624 Posts.

2468

14/09/20

17:09

Post #: 47330036
Share

Originally posted by YLJ: ↑

Good morning and good questions.

I'm sure a lot of people saw what I pointed out on that Wednesday bar a warning sign.
The failure to hold 0.78 after the top, as you mentioned was also a signal for some.
Some took profit right then (a valid intraday signal to do so) other took profit on the bounce
(such a bounce is common enough before the next leg down, which I why I believe it did not
succeed in retesting 0.97. There are day traders who will take profit on any strong daily move
regardless. I also think $1 is a significant physiological level and 0.97 is close
enough. If one tries to only take profits at exact numbers (however they are derived), it is usually
detrimental. Excuse all the down ramping lol...

If there was a perfect science to it, I would be richer than Bill Gates lol.
I do not believe it is possible to accurately pick tops consistently.
The first thing in protecting capital is not to keep real losses as small as possible.
The erasing part of paper gains is also a form of capital protection but a much more
difficult one. The trader who I respect most of all often says that the hardest trades
to manage are the winners, not the losers. Nothing could be more true. I do not
ever expect to fully master that aspect of trading and I am okay with that.

On a regular trade, I take partial (sometimes entire) profits at targets (which are usually
measured moves from chat patterns). If it shoots up through those levels I edge up my
stops incrementally unless we hit a major resistance where I will close out completely.
I often miss some further upside, but more often save myself from a drawdown.
At a certain point, there are factors in profit-taking that have more to do with money
management than with technicals. Nothing is accurate enough overtime to trump taking
(at least) some major gains off the table, even when there is some technical possibility of
further upside. The large percentage fluctuations between relatively close levels are the
difficulty of trading low priced stocks (works to the upside that way too though thankfully)...
I do not see how one can be a "LTH" and avoid the possibility of a 20% drawdown on stock
priced at these levels and still want to be an LTH.. It's a catch 22.
If that is the goal, best to use a trailing stop after a strong move but that is not an LTH strategy.
A lot of what I would say would depend on your entry price and some other factors...
It is precisely because there is no prophecies in technicals that those factors play a role.
All the best.

Expand

Great post YLJ

BRN Price at posting: 67.0¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

OJC

SPC to merge with Original Juice Co and Nature One Dairy

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 18,836 more messages in this thread...

First 2071 Last

Add BRN (ASX) to my watchlist

(20min delay)
Last 25.5¢		Change 0.020(8.51%)		Mkt cap ! $500.4M

Open	High	Low	Value	Volume
22.5¢	27.5¢	22.0¢	$8.399M	33.52M

Buyers (Bids)

No.	Vol.	Price($)
6	338805	25.5¢

Sellers (Offers)

Price($)	Vol.	No.
26.0¢	10000	1

View Market Depth

No.	Vol.	Price($)
6	338805	0.255
15	429045	0.250
13	731308	0.245
9	88244	0.240
6	93087	0.235

Price($)	Vol.	No.
0.260	10000	1
0.265	231580	5
0.270	636408	10
0.275	501185	11
0.280	1156121	31

Last trade - 16.10pm 02/10/2024 (20 minute delay)

BRN (ASX) Chart

Chart, page-2071

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SPC to merge with Original Juice Co and Nature One Dairy

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Chart, page-2071

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SPC to merge with Original Juice Co and Nature One Dairy

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News